Impact of minimal residual disease (MRD) status in clinical outcomes of patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) treated with inotuzumab ozogamicin (InO) in the phase 3 INO-VATE trial.

Elias Jabbour, Hagop M. Kantarjian, Matthias Stelljes et al.|Journal of Clinical Oncology|2018

Cited by 6